Arcus Biosciences Inc (RCUS)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.37 | 2.29 | 2.16 | 2.09 | 2.05 | 1.99 | 1.98 | 1.94 | 1.89 | 1.55 | 1.49 | 1.41 | 1.54 | 1.49 | 1.12 | 1.25 | 1.24 | 1.22 | 1.22 | 1.17 |
Arcus Biosciences Inc consistently maintains low solvency ratios across various quarters, as reflected in the debt-to-assets, debt-to-capital, and debt-to-equity ratios, all of which are reported as 0.00. This signifies that the company operates with minimal debt in relation to its assets, capital, and equity, indicating a strong balance sheet structure and financial stability.
In terms of the financial leverage ratio, Arcus Biosciences Inc has shown a stable upward trend from Q1 2022 to Q4 2023, increasing from 1.94 to 2.37. The financial leverage ratio measures the extent to which the company relies on debt to finance its operations, and an increasing ratio suggests a higher dependence on debt. While the financial leverage ratio has been rising, it is still within a moderate range, indicating that the company's debt levels have been managed prudently and are not at concerning levels.
Overall, based on the solvency ratios provided, Arcus Biosciences Inc appears to have a solid financial position with low debt levels, which can contribute to greater financial flexibility and resilience in times of economic uncertainty. The increasing trend in the financial leverage ratio should be monitored for any potential impacts on the company's financial health in the future.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -85.00 | -107.67 | -123.47 | -98.16 | -114.90 | 44.21 | 57.56 | 91.78 | 207.69 | — | — | — | — | — | — | — | — | -17.20 | -14.95 | -12.25 |
I'm sorry, but without specific data for interest payments and earnings before interest and taxes (EBIT) for Arcus Biosciences Inc across the given quarters, it is not possible to calculate or analyze the interest coverage ratio. As the interest coverage ratio is a measure of a company's ability to meet its interest payments on outstanding debt, the absence of the necessary financial data prevents a detailed analysis.